DENTSPLY SIRONA (XRAY) Upgraded at J P Morgan Chase & Co

J P Morgan Chase & Co upgraded shares of DENTSPLY SIRONA (NASDAQ:XRAY) from a neutral rating to an overweight rating in a research note released on Wednesday, MarketBeat reports. They currently have $75.00 target price on the medical instruments supplier’s stock.

A number of other research analysts have also recently weighed in on the stock. Deutsche Bank assumed coverage on shares of DENTSPLY SIRONA in a research report on Friday, December 8th. They set a buy rating and a $81.00 price target on the stock. HC Wainwright reaffirmed a hold rating and set a $68.00 price target on shares of DENTSPLY SIRONA in a research report on Thursday, December 7th. BidaskClub cut shares of DENTSPLY SIRONA from a strong-buy rating to a buy rating in a research report on Saturday, December 2nd. Stephens started coverage on shares of DENTSPLY SIRONA in a research note on Tuesday, November 28th. They set an overweight rating and a $75.00 price objective on the stock. Finally, TheStreet upgraded shares of DENTSPLY SIRONA from a c rating to a b- rating in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company. The company currently has an average rating of Buy and an average target price of $69.31.

DENTSPLY SIRONA (NASDAQ XRAY) opened at $66.48 on Wednesday. The firm has a market cap of $15,269.33, a P/E ratio of 26.49, a price-to-earnings-growth ratio of 2.63 and a beta of 1.31. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.59 and a current ratio of 2.32. DENTSPLY SIRONA has a 12-month low of $52.53 and a 12-month high of $68.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $978.99 million. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. DENTSPLY SIRONA’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.66 earnings per share. equities research analysts predict that DENTSPLY SIRONA will post 2.65 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 12th. Stockholders of record on Friday, December 29th will be paid a dividend of $0.0875 per share. The ex-dividend date is Thursday, December 28th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 0.53%. DENTSPLY SIRONA’s dividend payout ratio is currently -10.09%.

In other news, insider Mark Thierer acquired 77,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were bought at an average price of $66.04 per share, for a total transaction of $5,085,080.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Nicholas W. Alexos acquired 50,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were purchased at an average price of $65.85 per share, for a total transaction of $3,292,500.00. The disclosure for this purchase can be found here. Company insiders own 1.99% of the company’s stock.

Large investors have recently modified their holdings of the stock. Veritas Asset Management LLP increased its stake in shares of DENTSPLY SIRONA by 2.6% in the second quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock worth $402,083,000 after buying an additional 157,616 shares during the last quarter. Bronfman E.L. Rothschild L.P. increased its stake in shares of DENTSPLY SIRONA by 78.7% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 11,886 shares of the medical instruments supplier’s stock worth $771,000 after buying an additional 5,236 shares during the last quarter. Royce & Associates LP increased its stake in shares of DENTSPLY SIRONA by 23.4% in the second quarter. Royce & Associates LP now owns 126,650 shares of the medical instruments supplier’s stock worth $8,212,000 after buying an additional 24,000 shares during the last quarter. Delta Lloyd Asset Management N.V. bought a new stake in shares of DENTSPLY SIRONA in the second quarter worth $15,624,000. Finally, Grandfield & Dodd LLC increased its stake in shares of DENTSPLY SIRONA by 1.8% in the third quarter. Grandfield & Dodd LLC now owns 236,109 shares of the medical instruments supplier’s stock worth $14,122,000 after buying an additional 4,140 shares during the last quarter. Institutional investors and hedge funds own 96.58% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “DENTSPLY SIRONA (XRAY) Upgraded at J P Morgan Chase & Co” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/12/17/dentsply-sirona-xray-upgraded-at-j-p-morgan-chase-co.html.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply